CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 224 enrolled
Drug / intervention
Unasyn +1 moredrug
Likely dose
Unasyn 50mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00760006
NCT00760006Phase 2Completed

Efficacy of Preoperative Prophylactic Antibiotics in Preventing Complications in the Primary Repair of Cleft Palates

Joseph Losee·interventional·Posted Sep 25, 2008·Updated Feb 1, 2018

In Brief

A Phase 2 clinical trial evaluating Unasyn and saline solution for Cleft Palates. Completed, enrolled 224 participants across 1 site.

Detailed Summary

The primary objective of this study is to determine the efficacy of administering a single dose of preoperative antibiotics to prevent complications in patients undergoing primary closure of a cleft secondary palate. Secondary objective of this study is to evaluate the effects of preoperative antibiotics administered on post operative outcome following primary closure of cleft secondary palate. The study aims to assess the efficacy of prophylactic antibiotics in cleft surgery to * decrease the incidence of surgical sight infections * speed the progression of postoperative healing * improve the final quality of wound healing achieved * decrease the rate of palatal fistula formation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCleft Palates
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 25, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 17.8 years ago

Interventions

Unasyndrug

Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm

saline solutionother

Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.